Updated guidance
NAMS, ACOG, and Endocrine Society agree: individualize duration. Annual benefit-risk review. Symptoms recur after stopping in ~50%. Bone density loss accelerates after stopping unless on bisphosphonate.
Tapering vs stopping
Some clinicians taper gradually. Others stop cold turkey. Evidence inconsistent on either. Symptoms can return with either approach if hormones still needed.
Was this helpful?